QTTB

Q32 Bio Inc. QTTB

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #1,372 of 2,925TOP 50%

Why it scores 54Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Top Institutional Holders

as of Q2 2026
$282.56M total
ORBIMED ADVISORS LLC
$52.59M+83.2%
Boxer Capital Management, LLC
$40.12MNew
Atlas Venture Life Science Advisors, LLC
$34.62M+29.9%
BVF INC/IL
$29.94MNew
RA CAPITAL MANAGEMENT, L.P.
$29.72MNew
Point72 Asset Management, L.P.
$14.95MNew
Opaleye Management Inc.
$11.86M-25.9%
Logos Global Management LP
$10.19MNew
SummitTX Capital, L.P.
$9.35MNew
VANGUARD CAPITAL MANAGEMENT LLC
$6.61M+69.3%
Ikarian Capital, LLC
$5.48MNew
Woodline Partners LP
$3.65MNew
AMERICAN CENTURY COMPANIES INC
$3.47M+1353.1%
Sanofi
$3.11M0.0%
ACADIAN ASSET MANAGEMENT LLC
$2.78M+26.4%
ACORN CAPITAL ADVISORS, LLC
$2.75M-31.4%
RENAISSANCE TECHNOLOGIES LLC
$2.29M-13.2%
JANE STREET GROUP, LLC
$2.07M+148.1%
MONIMUS CAPITAL MANAGEMENT, LP
$1.68M-1.7%
BOOTHBAY FUND MANAGEMENT, LLC
$1.66MNew
GEODE CAPITAL MANAGEMENT, LLC
$1.56M+3.8%
CITADEL ADVISORS LLC
$1.54M+679.4%
BlackRock, Inc.
$1.51M+37.6%
MARSHALL WACE, LLP
$854.2K+27.9%
VANGUARD FIDUCIARY TRUST CO
$843.6K+32.4%
See all 71 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/QTTB

Earnings Per Share

13fpro.ai/company/QTTB

Loading ratio trend…

QTTB key financials by period

Reported revenue, net income and operating margin by fiscal year, from Q32 Bio Inc.'s annual filings on SEC EDGAR.

Q32 Bio Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$53.7M$29.8M31.4%
FY 2023$-6.7M$-53.7M—
FY 2022$3.2M$-5.0M—
FY 2021$34.0M$-95.8M—
FY 2020$2.7M$-128.7M—
FY 2019$1.7M$-103.9M—
Source: QTTB filings on SEC EDGAR →

QTTB insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Q32 Bio Inc. (QTTB): stock profile, AI score and financials

Q32 Bio Inc. (QTTB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores QTTB at 53.9/100 on a composite quality score built from its SEC filings, placing it at rank #1,372 of 2,925 stocks — the top half of the AI-ranked universe. QTTB scores in the top quartile across profitability (99.9), balance sheet strength (98.9), institutional flow (92.0). Areas of concern include revenue scale (1.2) and free cash flow (2.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 15.9/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of QTTB by reported 13-F value include ORBIMED ADVISORS, Boxer Capital Management, Atlas Venture Life Science Advisors, based on the most recent SEC filings. QTTB trades on the Nasdaq exchange and files with the SEC under CIK 1661998. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate QTTB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Q32 Bio Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1661998 →